Values as of: 2024-11-02
COMMON STOCK | Health Information Services |
Last Closing
USD 8.529Change
0.00 (0.00)%Market Cap
USD 1.50BVolume
5.00Analyst Target
N/AVerdict
Verdict
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| L0T:F | GE HEALTHCARE TECH.INC. |
N/A |
USD 37.77B |
| 2HE:F | Healthequity Inc |
N/A |
USD 6.90B |
| 4YC:F | M3 INC. |
N/A |
USD 6.89B |
| 6HL0:F | R1 RCM Inc |
N/A |
USD 5.57B |
| 9EH:F | Evolent Health Inc |
N/A |
USD 2.44B |
| OC9:F | Omnicell Inc |
N/A |
USD 2.04B |
| 1KJ:F | 10X GENOMICS DL -00001 |
N/A |
USD 1.73B |
| 6JM:F | JMDC INC. |
N/A |
USD 1.69B |
| 1XZ:F | Ping An Healthcare and Technol.. |
N/A |
USD 1.55B |
| 19P:F | Phreesia Inc |
N/A |
USD 0.98B |
N/A
| Market Performance vs. Industry/Classification (Health Information Services) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -57.04% | 20% | F | 10% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -57.04% | 20% | F | 10% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -48.77% | 24% | F | 13% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -48.77% | 24% | F | 13% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -40.19% | 2% | F | 1% | F | ||
| Dividend Return | -40.19% | 2% | F | 1% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 27.73% | 48% | F | 48% | F | ||
| Risk Adjusted Return | -144.90% | 2% | F | N/A | F | ||
| Market Capitalization | 1.50B | 85% | B | 63% | D | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
